Skip to main content
PMC home page
Cytotechnology logoLink to Cytotechnology
. 1998 Nov;28(1-3):139–145. doi: 10.1023/A:1008094017583

Historical reflections on cell culture engineering

Anthony S Lubiniecki 1
PMCID: PMC3449839  PMID: 19003415

Abstract

Cell culture engineering has enabled the commercial marketing of about a dozen human therapeutic products derived from rDNA technology and numerous monoclonal antibody products as well. A variety of technologies have proven useful in bringing products to the marketplace. Comparisons of the technologies available 15 years ago are contrasted with those available today. A number of improvements in unit operations have greatly improved the robustness of the processes during the past 15 years. Further evolution of the technology is expected in several directions driven by commercial and regulatory pressures. Some problems remain for the next generation of cell culture engineers to solve.

Keywords: biopharmaceuticals, cell culture engineering, commercial manufacturing

Full Text

The Full Text of this article is available as a PDF (48.6 KB).

References

  1. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A, McArdle L, Chree A, Hope J, Birkett C, Cousens S, Fraser H, Bostock CJ. Transmission to mice indicate that ‘new variant’ CJD is caused by the BSE agent. Nature. 1997;389:498–501. doi: 10.1038/39057. [DOI] [PubMed] [Google Scholar]
  2. Burstyn DG. Contamination of genetically engineered Chinese Hamster Ovary cells. Dev Biol Standard. 1996;88:199–203. [PubMed] [Google Scholar]
  3. Curran JW, Morgan WM, Hardy AM, Jaffe HW, Darrow WW, Dowdle WR. The epidemiology of AIDS: current status and future prospects. Science. 1985;229:1352–1357. doi: 10.1126/science.2994217. [DOI] [PubMed] [Google Scholar]
  4. Garnick RL. Experience with viral contamination in cell culture. Dev Biol Standard. 1996;88:49–56. [PubMed] [Google Scholar]
  5. Hill AF, Desbruslais M, Joiner S, Sidle KCL, Gowland I, Collings J, Doey LJ, Lantos P. The same prion strain causes vCJD and BSE. Nature. 1997;389:448–450. doi: 10.1038/38925. [DOI] [PubMed] [Google Scholar]
  6. Hopps HE. Cell substrate issues - A historical perspective. In: Hopps HE, Petricciani JC, editors. Abnormal Cells. Gaithersburg: New Products, and Risk Tissue Culture Association; 1985. pp. 13–17. [Google Scholar]
  7. Lubiniecki AS. Safety considerations for cell culture-derived biologicals. In: Lydersen BK, editor. Large Scale Cell Culture. Munich: Carl Hanser; 1987. pp. 231–247. [Google Scholar]
  8. Lubiniecki AS. Potential influence of international harmonization of pharmaceutical regulations on biopharmaceutical development. Curr Opin Biotechnology. 1997;8:350–356. doi: 10.1016/S0958-1669(97)80016-X. [DOI] [PubMed] [Google Scholar]
  9. Lubiniecki AS, Lupker JH. Purified protein products of rDNA technology expressed in animal cell culture. Biologicals. 1994;22:161–169. doi: 10.1006/biol.1994.1022. [DOI] [PubMed] [Google Scholar]
  10. Miller HI. In: Regulatory Practice for Biopharmaceutical Production. Lubiniecki AS, Vargo SA, editors. New York: Wiley-Liss; 1995. pp. 13–32. [Google Scholar]
  11. Parkman PD. Safety of biopharmaceuticals: a current perspective. Dev Biol Standard. 1996;88:5–7. [PubMed] [Google Scholar]
  12. Petricciani JC. Regulatory considerations for products derived from the new biotechnology. Pharmaceutical Manufacturing. 1985;9:31–34. [Google Scholar]
  13. Petricciani JC, Regan PJ. Risk of neoplastic transformation from cellular DNA: Calculations using the oncogene model. Dev Biol Standard. 1986;68:43–49. [PubMed] [Google Scholar]
  14. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A. A new variant of CJD in the UK, Lancet. 1996;347:921–925. doi: 10.1016/s0140-6736(96)91412-9. [DOI] [PubMed] [Google Scholar]
  15. WHO Expert Committee on Biological Standardization, 47th Report, World Health Organization, Geneva.

Articles from Cytotechnology are provided here courtesy of Springer Science+Business Media B.V.

RESOURCES